Medicus Pharma Ltd. (MDCX)
| Market Cap | 16.11M -71.3% |
| Revenue (ttm) | n/a |
| Net Income | -51.22M |
| EPS | -2.37 |
| Shares Out | 55.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 655,485 |
| Open | 0.2920 |
| Previous Close | 0.3000 |
| Day's Range | 0.2900 - 0.3060 |
| 52-Week Range | 0.2500 - 7.7300 |
| Beta | -0.91 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+2,126.03%) |
| Earnings Date | May 14, 2026 |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was inco... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MDCX stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 2,126.03% from the latest price.
News
Medicus Pharma reports Q1 EPS (31c), consensus (22c)
“During the first quarter of 2026, Medicus continued to execute on its transformation into a diversified clinical-stage biotechnology company, highlighted by expanded positive Phase 2 SkinJect data, a...
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives Company Advances SkinJect® and Teverelix® Clinical...
Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis
Medicus Pharma (MDCX) announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase 2 SKNJCT-003 study evaluating safety and efficacy of doxorubi...
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs o...
Medicus Pharma meets with lawmakers to support SkinJect designations
Medicus Pharma (MDCX) announced that CEO Raza Bokhari, along with the Medicus leadership team, conducted a series of meetings on Capitol Hill with senior lawmakers across key healthcare committees to…
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients w...
Medicus Pharma initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $9 price target The firm projects growing revenue from the company’s doxorubicin- microneedle array in basal cell…
Medicus Pharma submits ODD application to U.S. FDA for SkinJect
Medicus Pharma (MDCX) announced the submission of an Orphan Drug Designation, ODD, application to the U.S. Food and Drug Administration for SkinJect, D-MNA, for the treatment of basal cell carcinoma,…
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinoma Targets rare, high-burden genetic condition with no ...
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women's Health Updated Safety, Efficacy, a...
Medicus Pharma enters media partnership with New to The Street
Medicus Pharma (MDCX) entered into a 12-part, one-year strategic media agreement with New to The Street to expand its national and international visibility across television, digital, and outdoor plat...
Medicus Pharma submits clinical study design to FDA for Teverelix
Medicus Pharma (MDCX) announced the company has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acut...
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market Mechanism-Driven Study Design Focu...
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancer Provides guidance on interpretation of Topline dataset and confirms focus ...
Medicus Pharma reports principal investigator validation of Phase 2 data
Medicus Pharma (MDCX) reported independent clinical validation of its Phase 2 SkinJect dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study. “In my view as principal investigator...
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer Dr. Babar Rao highlights clinically meaningful outco...
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer 200µg Cohort at Day 57 Dataset suggests m...
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. (NAS...
Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat
Medicus Pharma (MDCX) announced hat members of its executive management team, led by Dr. Raza Bokhari, Executive Chairman & CEO, will participate in a live fireside chat on Thursday, March…
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS New...
Medicus Pharma announces SkinJect Phase 2 KOL update
Medicus Pharma (MDCX) announced that Babar Rao, MD, FAAD, an internationally recognized academic dermatologist and Principal Investigator of the SKNJCT-003 Phase 2 clinical study, will join the Compan...
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medi...
Medicus Pharma provides interpretation of Phase 2 SkinJect dataset
Medicus Pharma (MDCX) provided additional context regarding the recently reported topline dataset from the Phase 2 SKNJCT-003 study evaluating SkinJect microneedle delivery of D-MNA and P-MNA for basa...
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57 The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57